Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model

Prostate

Volumn 50, Issue 4, 2002, Pages 222-235

  Igawa, Tsukasa ^a   Lin, Fen Fen ^b   Lee, Ming Shyue ^c   Karan, Dev ^a   Batra, Surinder K ^a   Lin, Ming Fong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NAGASAKI UNIVERSITY   (Japan)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Androgen independence; AR expression; Cell model; LNCaP cells; Prostate cancer; PSA secretion

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; STEROID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; CYTOGENETICS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANDROGENS; ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CYTOGENETIC ANALYSIS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; POLYMERASE CHAIN REACTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED;

EID: 0036187849     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10054     Document Type: Article

References (48)

1. Cancer statistics 2000
2. Endocrine treatment in prostate cancer
3. Hormone refractory prostate cancer
4. The biology of hormone refractory prostate cancer: Why does it develop?
5. Molecular genetics of prostate cancer
6. Model systems of prostate cancer: Uses and limitations
7. The LNCaP cell line: A new model for studies on human prostatic carcinoma
8. LNCaP model of human prostatic carcinoma
9. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest
10. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative
11. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system
12. Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells
13. LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis
14. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP
15. Regulation of prostatic acid phosphatase expression and secretion by androgen in LNCaP human prostate carcinoma cells
16. Differential responsiveness of prostatic acid phosphatase and prostate-specific antigen mRNA to androgen in prostate cancer cells
17. Expression of human prostatic acid phosphatase activity and the growth of prostate carcinoma cells
18. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines
19. Downstream of Crk adaptor signaling pathway: Activation of Jun kinase by v-Crk through the guanine nucleotide exchange protein C3G
20. Chromosome banding techniques
21. Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells
22. The expression of prostatic acid phosphatase is transcriptionally regulated in human prostate cancer cells
23. Mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens
24. Anti-androgens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heatshock protein interaction, and transcription activation
25. Hormone resistance in prostate cancer
26. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3227-H adenocarcinoma
27. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
28. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
29. Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system
30. Chromosomal changes associated with progression of the Dunning R-3327 rat prostatic adenocarcinoma system
31. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and G rat adenocarcinomas
32. Establishment of two human prostate cancer cell lines derived from a single bone metastasis
33. Human cell line as an in vitro/in vivo model for prostate carcinogenesis and progression
34. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells
35. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
36. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
37. Proto-oncogenes and tumor suppressor genes in human urological malignancies
38. The HER-2/NEU (C-ERBB-2) oncogene is not amplified and is rarely overexpressed in primary prostate cancer
39. Her-2-neu expression and progression toward androgen independence in human prostate cancer
40. HER2 protein expression and gene amplification in androgen-independent prostate cancer
41. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands
42. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): Evaluation by RNA blot analyses
43. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma
44. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells
45. Androgen-independent induction of prostatespecific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways
46. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells
47. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
48. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway